Dapagliflozin Beneficial for Heart Failure, Regardless of Frailty
MONDAY, April 25, 2022 -- Dapagliflozin reduces the risk for worsening heart failure or cardiovascular death, regardless of frailty status, according to a study published online April 26 in the Annals of Internal Medicine.
Jawad H. Butt, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2022 Category: Pharmaceuticals Source Type: news
Qternmet XR (Dapagliflozin, Saxagliptin, and Metformin Hydrochloride) - updated on RxList
Qternmet XR extended-release tablets for oral use contain dapagliflozin, saxagliptin, and metformin HCl. Learn about the uses for type 2 diabetes, side effects, usages, drug interactions, warnings, precautions, and more. (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Moves Generic Dapagliflozin a Step Closer to US Sales FDA Moves Generic Dapagliflozin a Step Closer to US Sales
The FDA added two different dose formulations of generic dapagliflozin to its Orange Book of therapeutic equivalents, but a patent barrier remains in place.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 24, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
Dapagliflozin in Patients With CKD, With and Without HF Dapagliflozin in Patients With CKD, With and Without HF
Heart failure is common in patients with chronic kidney disease. Might the SGLT-2 inhibitor dapagliflozin reduce the risk of kidney failure and cardiovascular death in these patients?JACC: Heart Failure (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 3, 2022 Category: Intensive Care Tags: Cardiology Journal Article Source Type: news
Dapagliflozin Reduces New-Onset T2D in Patients With CKD, HF Dapagliflozin Reduces New-Onset T2D in Patients With CKD, HF
In patients with chronic kidney disease and heart failure, dapagliflozin curbed the incidence of new-onset type 2 diabetes without reducing HbA1c in a pooled analysis of the DAPA-CKD and DAPA-HF trials.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 21, 2021 Category: Intensive Care Tags: Diabetes & Endocrinology News Source Type: news
Outrage Over Dapagliflozin Withdrawal for Type 1 Diabetes in EU Outrage Over Dapagliflozin Withdrawal for Type 1 Diabetes in EU
The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as ' appalling ' and ' devastating ' , with questions raised as to why it was pulled.Medscape Medical News (Source: Medscape Business of Medicine Headlines)
Source: Medscape Business of Medicine Headlines - December 15, 2021 Category: Pharmaceuticals Tags: Diabetes & Endocrinology News Source Type: news
Kidney patients offered new hope with a diabetes pill
NHS chiefs have granted roughly 91,000 sufferers access to the drug, dapagliflozin, which has slashed the risk of needing dialysis, a transplant and even death by up to 39 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - November 13, 2021 Category: Consumer Health News Source Type: news
NICE draft guidance recommends dapagliflozin for some patients with chronic kidney disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF Dapagliflozin Improves Physical Limitation in HFpEF: PRESERVED-HF
The SGLT2 inhibitor scored a clear win, showing a significant and clinically meaningful benefit after 12 weeks for the primary endpoint, a measure of symptoms and physical limitations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 14, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Dapagliflozin in HFrEF May Cut Arrhythmias, Sudden Death: DAPA-HF Dapagliflozin in HFrEF May Cut Arrhythmias, Sudden Death: DAPA-HF
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies among key subgroups.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 27, 2021 Category: Neurology Tags: Cardiology News Source Type: news
EU Approves Dapagliflozin for Kidney Disease, Regardless of Diabetes EU Approves Dapagliflozin for Kidney Disease, Regardless of Diabetes
The decision rested on results from the DAPA-CKD pivotal trial and followed US FDA approval last April for adults with chronic kidney disease regardless of whether they also have type 2 diabetes.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - August 10, 2021 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news
Dapagliflozin Safe, Protective in Advanced Kidney Disease Dapagliflozin Safe, Protective in Advanced Kidney Disease
' For clinicians, this is now the absolute reassurance that we do not have to stop an SGLT2 inhibitor ' in patients with advanced kidney disease, said Dr Chantal Mathieu, about the DAPA-CKD trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD
WEDNESDAY, July 21, 2021 -- For patients with stage 4 chronic kidney disease (CKD), a similar pattern of reduced kidney, cardiovascular, and mortality risks is seen with dapagliflozin versus placebo, with no evidence of increased risks, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 21, 2021 Category: Pharmaceuticals Source Type: news
Dapagliflozin's Cost-effectiveness'Intermediate' for HFrEF Dapagliflozin's Cost-effectiveness'Intermediate' for HFrEF
New analysis shows that despite reducing CV death in heart failure with reduced ejection fraction, the current cost of dapagliflozin makes it only an ' intermediate ' value in terms of cost-effectiveness.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
AstraZeneca Pharma, Abbott Healthcare terminate distribution agreements for diabetes drug in India
AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively, the filing said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 28, 2021 Category: Pharmaceuticals Source Type: news
